SUMMARY -Th e aim of this study was to demonstrate epidemiological, clinical and endoscopic characteristics of acute upper gastrointestinal bleeding (UGIB) with special reference to peptic ulcer bleeding (PUB). Th e study included 2198 consecutive patients referred to our emergency department due to acute UGIB from January 2008 to December 2012. All patients underwent urgent upper GI endoscopy within 24 hours of admission, and 842 patients diagnosed with PUB were enrolled and prospectively followed-up. Th e cumulative incidence of UGIB was 126/100,000 in the 5-year period. Two out of fi ve patients had a bleeding peptic ulcer; in total, 440 (52.3%) had bleeding gastric ulcer, 356 (42.3%) had bleeding duodenal ulcer, 17 (2%) had both bleeding gastric and duodenal ulcers, and 29 (3.5%) patients had bleeding ulcers on gastroenteric anastomoses. PUB was more common in men. Th e mean patient age was 65.9 years. Th e majority of patients (57%) with PUB were taking agents that attenuate the cytoprotective function of gastric and duodenal mucosa. Rebleeding occurred in 77 (9.7%) patients and 47 (5.9%) patients required surgical intervention. Th e 30-day morality was 5.2% and 10% of patients died from uncontrolled bleeding and concomitant diseases. In conclusion, PUB is the main cause of UGIB, characterized by a signifi cant rebleeding rate and mortality.
Introduction
Upper gastrointestinal bleeding (UGIB) is a common medical emergency and accounts for 5% of emergency department presentations per year and 2% to 3% of hospital admissions in developed countries 1 . Th e incidence rate of UGIB varies from 48 to 160 cases per 100,000 population, with consistent reports of higher incidence among men and the elderly 2 . Th e most common cause of acute UGIB is non-variceal, where peptic ulcer bleeding (PUB) accounts for 28% to 59% of cases [2] [3] [4] . Endoscopy has become the standard of care in the diagnosis and treatment of UGIB. Most national and international guidelines recommend performing upper endoscopy within 24 hours of presentation in patients with UGIB [5] [6] [7] . Despite major advances in diagnostic and therapeutic approaches, PUB remains a signifi cant problem and an important cause of morbidity and mortality. Rebleeding after initial hemostasis occurs in 10% to 30% of patients with PUB [8] [9] [10] [11] . Th e reported PUB mortality rates in various countries across Europe range from 3.4% to 14%, and the reason for this diff erence remains unknown [12] [13] [14] [15] . Th e aim of this prospective study was to determine the epidemiological, clinical and endoscopic characteristics of UGIB with a focus on the treatment and prognosis of PUB in a tertiary care center.
Patients and Methods
Th is prospective study was conducted in a tertiary care center in the City of Zagreb, Croatia, which covers a population of approximately 300,000 people. All consecutive patients presenting with UGIB (hematemesis, melena, hematochezia or blood admixture upon nasogastric aspiration) to the Emergency Internal Medicine Unit, Sestre milosrdnice University Hospital Center between January 2008 and December 2012 were included. Th ese patients were then, if necessary, hospitalized in the Interventional Gastroenterology Unit of the same hospital. If the same patient was hospitalized more than once during the study period, only the fi rst episode was counted as the incident case, irrespective of previous or subsequent episodes of PUB.
Upper gastrointestinal endoscopy was performed in all patients within 24 hours of hospital admission. Only patients with PUB confi rmed by endoscopy were prospectively followed-up for 30 days. After initial endoscopic examination, patients in whom endoscopic therapy had been performed were hospitalized. All patients received high-dose acid suppression therapy (pantoprazole or esomeprazole 80 mg intravenously as an initial bolus followed by 40 mg intravenously and/ or oral 3 times per day for at least 48 hours, followed by 40 mg daily per os).
Prior to endoscopy, a written informed consent was obtained from all patients or their relatives, which included possible risks, benefi ts and treatment options during the procedure. In addition, a written informed consent was obtained from patients or their relatives before trial entry. Th e study was approved by the Ethics Committee of the hospital. Data were collected prospectively into a database, with patient details stored in a depersonalized manner to protect patient confi dentiality.
Data collection
Th e following data were collected for each patient: demographic data, signs and characteristics of the bleeding episode, symptoms and history of ulcer or liver disease, coexisting illness, drug use, laboratory results, endoscopic diagnosis including the cause of bleeding, presence of fresh blood/clots or stigmata of recent hemorrhage, endoscopic intervention, medical treatment, rebleeding incidence, surgical therapy, duration of hospitalization and cause of death. Shock was defi ned as syncope or signs of shock upon physical examination, including systolic blood pressure <100 mm Hg or heart rate >100 beats/min.
Grading of overall health and comorbidity was performed according to the American Society of Anesthesiology (ASA) classifi cation (grade 1, normal healthy patients; grade 2, mild systemic illness; grade 3, severe, but incapacitating systemic illness; and grade 4, life-threatening illness). Stigmata of recent hemorrhage were defi ned according to Forrest classifi cation as follows: Forrest Ia, spurting bleeding; Forrest Ib, oozing bleeding; Forrest IIa, non-bleeding visible vessel; Forrest IIb, adherent clot; Forrest IIc, hematin on ulcer base; and Forrest III, clean ulcer base 16 . Th e size of ulcer was classifi ed as <2 cm or ≥2 cm. Th e commonly used hemostatic procedures were epinephrine injections (1:10000 solution of epinephrine) and/or mechanical hemostasis with stainless steel hemoclips (Olympus, Japan) and/or thermocoagulation with a heater probe (Olympus, 7F, 20-30 joules).
Two biopsy specimens were obtained from the gastric antrum and body in all patients and the presence of Helicobacter pylori (H. pylori) infection was assessed by histopathologic examination of the specimens using hematoxylin-eosin (HE) stain. In all patients with gastric ulcers in whom recurrent bleeding was not observed, follow-up endoscopy was performed four to fi ve days after initial hemostasis and biopsy specimens were ob-tained from the margins and base of gastric ulcers to exclude malignancy. Follow-up endoscopy with histology was planned in all patients with gastric ulcers. In all patients with negative histology for H. pylori at index endoscopy, urea breath test (UBT) or follow-up endoscopy with histology was performed 2 weeks after proton pump inhibitor (PPI) treatment had been discontinued. Patients were considered positive for H. pylori infection in case of positive histology or positive UBT.
Clinical outcomes of PUB were analyzed according to the rebleeding rate, need for surgical intervention, need for blood transfusion, length of hospital stay, and 30-day mortality.
Rebleeding was defi ned as one or more signs of ongoing bleeding, including fresh hematemesis or melena, hematochezia, aspiration of fresh blood via nasogastric tube, instability of vital signs, and reduction of hemoglobin or hematocrit levels by more than 2 g/dL or 5%, respectively, over a 24-hour period after primary bleeding was stopped. Patients that had unsuccessful initial endoscopic treatment or more than two successful retreatments underwent emergency surgery.
Statistics
All analyses were performed with the Statistica 11.0 (Statsoft, Inc., Tulsa, OK) for Windows statistical package. Th e Mann-Whitney U-test and KruskalWallis ANOVA test were used as nonparametric tests where appropriate, and a p-value <0.05 was considered signifi cant. Th e predictive value of qualitative variables on mortality and rebleeding was studied in univariate analysis using Pearson χ 2 -test, when appropriate. Multivariate analysis was conducted using a forward elimination logistic regression model to identify a fi nal set of variables independently associated with either mortality or rebleeding. A signifi cance level α=0.05 was used to retain variables in the multivariate model. All results were presented as odds ratios (ORs) with the associated 95% confi dence intervals (95% CIs).
Results
From January 2008 to December 2012, 2198 patients with UGIB were analyzed; 89.5% of patients had non-variceal bleeding, 8.3% had variceal bleeding, and in 2.2% the source was not identifi ed.
In the group of patients with non-variceal bleeding, 42.8% had bleeding ulcer, while 57.2% had nonulcer bleeding (Mallory-Weis tear, angiomata, Dieulafoy's lesion, malignancy, acute erosive gastropathy, refl ux esophagitis, portal hypertensive gastropathy, arterial enteric fi stula). In patients with bleeding ulcers, 94.6% of cases were attributed to gastric or duodenal ulcers, 2% to both gastric and duodenal ulcers, and 3.4% to ulcer on previous gastroenteric anastomoses (Fig. 1) .
Th e cumulative incidence of UGIB in the observed 5-year period was 126/100,000. In the group of 796 patients that were carefully followed-up, 55.3% had bleeding from gastric ulcers and 44.7% from duodenal ulcers. Th e mean patient age was 65.9 years and men had a higher incidence of bleeding (62.9% vs. 37.1%; p<0.001). High risk ulcers (Forrest Ia-IIb) were verifi ed in 52% of patients, most ulcers were >2 cm in diameter, 9.7% of patients presented with shock, and 57.9% of patients had moderate to severe comorbidities. When analyzed according to medication usage, 28.3% of patients with peptic ulcers had been taking non-steroidal anti-infl ammatory drugs (NSAIDs), 20.3% acetylsalicylic acid, 2.6% anti-aggregation medication, 5.8% anti-coagulation therapy, and 9.2% gastroprotective medication (histamine 2 blockers or PPI). H. pylori testing was performed in 531 (66.7%) patients of which 220 (41.4%) tested positive. Th e presence of H. pylori infection was more common in patients with duodenal peptic ulcer (46.7% vs. 36.9%), which was statistically signifi cant (p<0.023) ( Table 1) .
Endoscopic treatment was performed in 456 (58.4%) patients; in 54.3% of cases hemostasis was achieved with hemoclips or with a combination of hemoclips and diluted epinephrine infi ltration. Rebleeding occurred in 9.7% of patients (Table 2) .
Th e risk of rebleeding was increased in patients with shock [OR 5.85 (Fig. 2) .
Forty-seven (5.9%) patients were transferred to the Department of Surgery (5 due to successful endoscop- ic hemostasis, 1 due to perforation during the procedure, and 41 due to recurrent bleeding). Most of the transferred patients had bleeding from the posterior wall of the duodenum, posterior proximal third of the gastric corpus, and from the small gastric curvature. Th e most common surgical procedure performed was mechanical hemostasis (ligation) and gastric resection. Th e total 30-day mortality was 5.2%. (Fig. 3 ).
Only 1/10 patients died from bleeding out and half of them were treated with red blood cell transfusions. Th e median volume of red blood cell transfusion was 2.2 (1-6) units and the median hospital stay was 6 (1-45) days (Table 2) .
Discussion
Th ere has been a signifi cant decline in the incidence of PUB and its complications since the introduction of PPIs and H. pylori eradication therapy. A lower incidence was observed in Sweden from 1987 to 2004 in both men and women, and one study conducted in the Netherlands found a decline from 61/100,000 to 48/100,000 per year from 1993 to 2000 17 . In Germany and the United Kingdom, the incidence of PUB has remained unchanged, but the average patient age has increased 18, 19 . In the Zagreb County, Croatia, the incidence of UGIB and PUB did not signifi cantly change from 2008 to 2012. Th is can be explained by the lower prevalence of H. pylori infection and increased use of drugs that aff ect the cytoprotective function of gastric mucosa (NSAIDs and acetylsalicylic acid), which has also been shown in other studies 20 . Th e average patient age in this study was higher than 65 years. In one study, Van Leerdam found that 70% of patients with UGIB were older than 60 years and 40% had several life-threatening diseases 4 , and in another one Van Leerdam et al. report that about 50% of patients with PUB were taking NSAIDs and acetylsalicylic acid, with only 12% of them taking PPI as protection 17 . H. pylori infection was diagnosed in 40% of patients and was found more frequently in patients with bleeding duodenal ulcers. In one prospective study conducted in the Netherlands, H. pylori testing was performed in 65% of patients with 43% having positive fi ndings, while a German study found that 56% of patients with PUB were H. pylori positive 18, 21 . Gralnek et al. found that PUB made up 28% to 59% of all UGIB. Half of the patients were categorized as high-risk ulcer patients (Forrest Ia, Ib, IIa and IIb) 22 . In a study by Bratanic et al., around 30% of patients were described as high-risk 23 . In our study, PUB represented about 40% of all non-variceal UGIB, and bleeding gastric ulcers were found more frequently than bleeding duodenal ulcers. Rebleeding after endoscopic treatment with endoclips or endoclips/diluted epinephrine occurred in 10% of patients and 5.9% of them required surgical intervention. Th e risk of recurrent bleeding was increased in patients with shock, actively bleeding ulcers, and ulcers larger than 2 cm in diameter. Our results are consistent with the results from other tertiary centers, and despite all endoscopic methods for hemostasis available, acute recurrent hemorrhage is still common, occurring in 10% to 28% of cases 24, 25 . We report a total 30-day mortality of 5.2%. Only 10% of patients died because of bleeding out, while others died from other comorbidities. Mortality was increased in patients with shock, recurrent bleeding ulcers larger than 2 cm in diameter, and moderate to severe comorbidities (ASA ≥3). Almost 60% of patients with PUB presented with moderate to severe comorbidities (ASA III and IV). When considering other studies, Marmo et al. report a PUB mortality rate of 4% to 5% in one prospective study 26 . Van Leerdam et al. showed that 40% of patients that died because of UIGB had one or several life-threatening comorbidities 17 . Marmo et al. showed that in the fi rst 24 hours of hospitalization, less than 30% of all patients died 26 . Villauneva et al. compared the effi cacy of a restrictive transfusion strategy (target hemoglobin 7-9 g/dL) with that of a liberal transfusion strategy (target hemoglobin 9-11 g/dL) in patients with acute gastrointestinal bleeding, fi nding that the probability of survival at 6 weeks was higher in the restrictive-strategy group 27 . Th is was also observed in a subgroup analysis of patients with PUB. Other authors also suggest better patient outcomes when the restrictive red blood cell transfusion strategy is used 8, [28] [29] [30] . In our study, half of the patients received red blood cell transfusions, with a median of 2.2 units.
Th e limitations of this study included diverse medical staff involved in endoscopic evaluation and treatment, resulting in inter-observer variability in endoscopic evaluation and treatment. Furthermore, this study had a short follow-up period of 30 days and was conducted in a tertiary center.
In conclusion, the incidence of UGIB and PUB remained unchanged in the observed period from 2008 to 2012, but we recorded an increase in the average age of PUB patients. Predictors of mortality in patients with PUB included shock, recurrent bleeding, ulcers larger than 2 cm in diameter, and moderate to severe comorbidities. Prevention of PUB, prompt intravascular volume replacement, early (≤24 hours) upper GI endoscopy, and a restrictive red blood cell transfusion strategy are important in the management of these patients.
